SOUTH PLAINFIELD, N.J., Dec. 18, 2013 /PRNewswire/ — Prolong Pharmaceuticals LLC, a biopharmaceutical company dedicated to developing products to treat several diseases and their debilitating comorbidities which cause reduced quality of life, increased medical costs and mortality, today announced the addition of Ronald G. Jubin, Ph.D. to their executive team as Managing Director, Research and Development. In his new role, Dr. Jubin will be responsible for pre-clinical discovery, methods development and the advancement of Prolong’s pipeline candidates.
“Ron brings more than two decades of experience at the forefront of drug discovery to our efforts here at Prolong,” said Dr. Abraham Abuchowski, Prolong’s Chief Scientific Officer and CEO. “We are excited to bring him on board at this important time in our company history.” In October, Prolong presented Phase I data for its flagship product SANGUINATE an intravenous therapeutic that combines the beneficial functions of a carbon monoxide releasing molecule with an oxygen transfer agent as well as acting as a plasma expander. SANGUINATE was found to be well tolerated with no serious adverse events, and is now moving forward into Phase II trials in patients with sickle cell disease who suffer from painful vaso-occlusive crises.
Dr. Jubin’s experience includes key roles at Schering-Plough Research Institute and PBL Biomedical labs. At Schering-Plough, he served in major roles in the hepatitis C protease program, directed other HCV inhibitor programs and managed internal committees evaluating novel interferon candidate licensing opportunities. At PBL Biomedical, his tenure leading the R&D department at PBL resulted in the development of numerous interferon proteins, reagents and functional assay for evaluating immune and interferon functions. Dr. Jubin received his Ph.D. in Microbiology and Molecular Genetics from the UMDNJ-NJMS Graduate School of Biomedical Sciences, Newark, NJ.
“This is an opportunity to work with the inventors of the world’s leading drug delivery technology, PEGYLATION, at its birthplace here inNew Jersey,” said Dr. Jubin. “This is the sort of environment where historic, groundbreaking drug developments occur, and I am looking forward to being a part of the leadership team.”
SANGUINATE is an investigational biopharmaceutical product that has a multiple mechanisms of action designed to release therapeutic carbon monoxide and actively transfer oxygen to hypoxic tissue. SANGUINATE has completed Phase I safety trials and is beginning trials in SCD patients.
About Prolong Pharmaceuticals
Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals LLC is developing products to treat several diseases and their debilitating comorbidities which cause reduced quality of life, increased medical cost and significant mortality. The company’s lead product, SANGUINATE™, is in clinical testing, focused on treating the comorbidities of sickle cell disease and other disorders where oxygen deprivation due to hemolysis and/or ischemia occurs. The company’s senior management team includes inventors of the most successful drug delivery technology in pharmaceutical history, PEGylation, now responsible for more than $30 billion in drug sales worldwide. For more information visit: www.prolongpharma.com.
Click Here for link to original article.